• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-authors' reply.

作者信息

Raschi Emanuel, Diemberger Igor, Cosmi Benilde, De Ponti Fabrizio

机构信息

Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Via Irnerio, 48, 40126, Bologna, Italy.

Department of Specialist, Diagnostic and Experimental Medicine, Institute of Cardiology, S.Orsola-Malpighi University Hospital, Alma Mater Studiorum - University of Bologna, Bologna, Italy.

出版信息

Intern Emerg Med. 2018 Jun;13(4):635-636. doi: 10.1007/s11739-018-1853-7. Epub 2018 Apr 25.

DOI:10.1007/s11739-018-1853-7
PMID:29696520
Abstract
摘要

相似文献

1
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-authors' reply.欧洲心脏病学会关于癌症治疗心血管毒性的立场文件：挑战与期望——作者回应
Intern Emerg Med. 2018 Jun;13(4):635-636. doi: 10.1007/s11739-018-1853-7. Epub 2018 Apr 25.
2
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-comment.欧洲心脏病学会关于癌症治疗心血管毒性的立场文件：挑战与期望——评论
Intern Emerg Med. 2018 Jun;13(4):633-634. doi: 10.1007/s11739-018-1838-6. Epub 2018 Mar 27.
3
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations.ESC 立场文件：癌症治疗的心血管毒性：挑战与期待
Intern Emerg Med. 2018 Jan;13(1):1-9. doi: 10.1007/s11739-017-1755-0. Epub 2017 Sep 23.
4
Overestimation of cardiovascular outcome incidence - Authors' reply.心血管结局发生率的高估——作者回复
Lancet. 2017 Dec 9;390(10112):2547. doi: 10.1016/S0140-6736(17)33085-4. Epub 2017 Dec 8.
5
Patient-doctor engagement in cardiovascular prevention - Authors' reply.医患在心血管疾病预防方面的参与度——作者回复
Lancet. 2019 Aug 24;394(10199):e27. doi: 10.1016/S0140-6736(19)31335-2.
6
Cardiovascular risk in hypertension: open questions about HOPE 4 - Authors' reply.
Lancet. 2020 Aug 1;396(10247):310-311. doi: 10.1016/S0140-6736(20)30616-4.
7
Influenza vaccination and prevention of cardiovascular disease mortality - Authors' reply.流感疫苗接种与心血管疾病死亡率的预防——作者回复
Lancet. 2018 Feb 3;391(10119):427-428. doi: 10.1016/S0140-6736(18)30144-2.
8
[2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity].[2016年欧洲心脏病学会关于癌症治疗与心血管毒性的立场文件]
Dtsch Med Wochenschr. 2017 Dec;142(24):1826-1830. doi: 10.1055/s-0043-112775. Epub 2017 Dec 5.
9
Frontiers in Cardiovascular Biology. Abstracts of the First Congress of the ESC Council on Basic Cardiovascular Science. Berlin, Germany. July 16-19, 2010.《心血管生物学前沿》。欧洲心脏病学会基础心血管科学委员会第一届大会摘要。德国柏林。2010年7月16日至19日。
Cardiovasc Res. 2010 Jul 15;87 Suppl 1:S43-135. doi: 10.1093/cvr/cvq164.
10
Frontiers in cardiovascular biology. Abstracts of the Third Congress of the ESC Council on Basic Cardiovascular Science. July 4-6, 2014. Barcelona, Spain.
Cardiovasc Res. 2014 Jul 15;103 Suppl 1:S1-160. doi: 10.1093/cvr/cvu074.1.

引用本文的文献

1
ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO).意大利心脏病学协会立场文件：新冠疫情时代的心衰与癌症共病（CO与CO）
Eur Heart J Suppl. 2021 Aug 26;23(Suppl C):C128-C153. doi: 10.1093/eurheartj/suab067. eCollection 2021 Aug.
2
Epigenetic Mechanisms Involved in the Cardiovascular Toxicity of Anticancer Drugs.参与抗癌药物心血管毒性的表观遗传机制
Front Cardiovasc Med. 2021 Apr 27;8:658900. doi: 10.3389/fcvm.2021.658900. eCollection 2021.
3
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia.

本文引用的文献

1
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-comment.欧洲心脏病学会关于癌症治疗心血管毒性的立场文件：挑战与期望——评论
Intern Emerg Med. 2018 Jun;13(4):633-634. doi: 10.1007/s11739-018-1838-6. Epub 2018 Mar 27.
2
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations.ESC 立场文件：癌症治疗的心血管毒性：挑战与期待
Intern Emerg Med. 2018 Jan;13(1):1-9. doi: 10.1007/s11739-017-1755-0. Epub 2017 Sep 23.
3
Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.
新冠疫情时代心房颤动与癌症的综合管理：药物相互作用、血栓栓塞风险及心律失常
Curr Heart Fail Rep. 2020 Dec;17(6):365-383. doi: 10.1007/s11897-020-00485-9.
4
Subclinical Arteriosclerosis is Associated With Common Vascular Risk Factors in Long-Term Survivors of Testicular Cancer.亚临床动脉硬化与睾丸癌长期幸存者的常见血管危险因素相关。
J Clin Med. 2020 Mar 31;9(4):971. doi: 10.3390/jcm9040971.
慢性髓性白血病的BCR-ABL酪氨酸激酶抑制剂与心血管事件、主要分子反应及总生存期之间的关联：一项系统评价和荟萃分析
JAMA Oncol. 2016 May 1;2(5):625-632. doi: 10.1001/jamaoncol.2015.5932.
4
Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis.酪氨酸激酶抑制剂治疗慢性髓性白血病患者的主要动脉事件：一项荟萃分析。
Leuk Lymphoma. 2016;57(6):1300-10. doi: 10.3109/10428194.2015.1091929. Epub 2015 Oct 20.
5
Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.酪氨酸激酶抑制剂与代谢相关的药代动力学药物相互作用：当前认识、挑战与建议
Br J Clin Pharmacol. 2015 Feb;79(2):241-53. doi: 10.1111/bcp.12496.